Data ownership as leverage in accelerating rare disease drug development? Finally, there’s a cloud software that empowers patient groups!

Patient groups can optimize patient registries, cross-sectional studies, and/or longitudinal natural history studies to maximize collaborations with sponsors of orphan drugs and gene therapies A disease is considered rare if it affects fewer than 200,000 people in the United States. There are over 8,000 named rare diseases and each year, Read more…